Clinically, these findings suggest two translational avenues: 1) Assessing MCPIP1 expression in circulating macrophages as a biomarker of cardiosplenic axis dysregulation post‐MI, and 2) Developing therapies targeting splenic macrophage output to modulate infarct zone inflammation. This evidence concerns the gene ZC3H12A and myocardial infarction.